CoChat

Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits liver health

Open access
Chen, Karen Lee Ann, Zhao, Yiru Chen, Hieronymi, Kadriye, Smith, Brandi Patricia, Madak-Erdogan, Zeynep · 2017 · PLOS ONE

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

The bazedoxifene and conjugated estrogens (CE+BZA) combination has been shown to prevent visceral adiposity and weight gain after ovariectomy. However, its impact on the liver transcriptomes associated with prevention of hepatosteatosis is yet to be determined. In the present study, we use liver transcriptomics and plasma metabolomics analysis to characterize the effects of various estrogens on liver. The CE+BZA combination was very effective at preventing ovariectomy-induced weight gain in mice fed a high-fat diet (HFD). In CE+BZA treated animals, liver weight and hepatic lipid deposition were significantly lower than in Vehicle (Veh) treated animals. Additionally, CE+BZA induced unique liver transcriptome and plasma metabolome profiles compared to estradiol, conjugated estrogens alone, and bazedoxifene alone. Blood plasma metabolite analysis identified several metabolites similar to and distinct from other estrogen treatments. Integrated pathway analysis showed that gene networks that were associated with inflammation, reactive oxygen species pathway and lipid metabolism and their relevant metabolites were regulated significantly by CE+BZA treatment. Thus, long-term CE+BZA treatment modulated hepatic metabolic gene networks and their associated metabolites and improves hepatic health without stimulating the uterus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0189911

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 CE+BZA combination decreases ovariectomy-associated weight gain and lipid deposition without stimulating reproductive tissue. (A) Total body weight change was measured at the end of six weeks of various estrogen treatments. (B) Fat mass was measured using EchoMRI at the end of four weeks of various estrogen treatments. (C) Uterus and (D) liver were harvested at the end of six weeks and weighed. (E) WAT, SAT, MAT, and KAT were harvested and weighed. All data were normally distributed. Statistical significance was established at α = 0.05. Pairwise t tests with a Bonferroni correction were used to identify treatments that were significantly different from Veh (*P < 0.05, **P < 0.01, ***P <0.001, ****P<0.0001).
Fig 1 CE+BZA combination decreases ovariectomy-associated weight gain and lipid deposition without stimulating reproductive tissue. (A) Total body weight change was measured at the end of six weeks of various estrogen treatments. (B) Fat mass was measured using EchoMRI at the end of four weeks of various estrogen treatments. (C) Uterus and (D) liver were harvested at the end of six weeks and weighed. (E) WAT, SAT, MAT, and KAT were harvested and weighed. All data were normally distributed. Statistical significance was established at α = 0.05. Pairwise t tests with a Bonferroni correction were used to identify treatments that were significantly different from Veh (*P < 0.05, **P < 0.01, ***P <0.001, ****P<0.0001).CC BY · PubMed Central
Fig 2 Lipid accumulation is decreased in mouse liver tissue after CE+BZA treatment. (A) H+E and Oil Red O staining of liver tissue from ovariectomized animals treated with various estrogens. Quantification of lipid droplet size (B) and number (C) by Fiji software. (D) Pearson correlations for lipid droplet size, body weight change, liver weight, and lipid droplet number were calculated. Statistical significance was established at α = 0.05. Pairwise t tests with a Bonferroni correction were used to identify treatments that were significantly different from Veh (***P <0.001, ****P<0.0001).
Fig 2 Lipid accumulation is decreased in mouse liver tissue after CE+BZA treatment. (A) H+E and Oil Red O staining of liver tissue from ovariectomized animals treated with various estrogens. Quantification of lipid droplet size (B) and number (C) by Fiji software. (D) Pearson correlations for lipid droplet size, body weight change, liver weight, and lipid droplet number were calculated. Statistical significance was established at α = 0.05. Pairwise t tests with a Bonferroni correction were used to identify treatments that were significantly different from Veh (***P <0.001, ****P<0.0001).CC BY · PubMed Central
Fig 3 CE+BZA treatment regulates common and unique groups of genes in mice liver. Mice were treated with vehicle E2, CE only, BZA only, or CE+BZA for 6 weeks. (A) Heat map of relative fold change of genes from hepatic RNA-Seq analysis using genes that were significantly different then Veh group with P < 0.05 and expression fold change >2 (n = 3 biological replicates). Genes were clustered using Cluster 3 and visualized using Treeview Java (B) PCA analysis of differentially regulated genes from different treatment groups. (C) Venn diagram analysis of gene lists that are differentially regulated in various estrogen treatment groups compared to Veh group. (D) Volcano plots of gene expression data to show genes significantly affected by various estrogen treatments relative to Veh treatment. Statistical significance was determined at α = 0.05 and greater than a 2-fold change. Significantly downregulated genes are highlighted in blue and upregulated genes are highlighted in red. (E) qPCR validation of RNA-seq results. Statistical significance was established at α = 0.05. Results were analysed using unpaired t- tests (*P < 0.05, **P < 0.01).
Fig 3 CE+BZA treatment regulates common and unique groups of genes in mice liver. Mice were treated with vehicle E2, CE only, BZA only, or CE+BZA for 6 weeks. (A) Heat map of relative fold change of genes from hepatic RNA-Seq analysis using genes that were significantly different then Veh group with P < 0.05 and expression fold change >2 (n = 3 biological replicates). Genes were clustered using Cluster 3 and visualized using Treeview Java (B) PCA analysis of differentially regulated genes from different treatment groups. (C) Venn diagram analysis of gene lists that are differentially regulated in various estrogen treatment groups compared to Veh group. (D) Volcano plots of gene expression data to show genes significantly affected by various estrogen treatments relative to Veh treatment. Statistical significance was determined at α = 0.05 and greater than a 2-fold change. Significantly downregulated genes are highlighted in blue and upregulated genes are highlighted in red. (E) qPCR validation of RNA-seq results. Statistical significance was established at α = 0.05. Results were analysed using unpaired t- tests (*P < 0.05, **P < 0.01).CC BY · PubMed Central
Fig 4 Gene ontology (GO) analysis of gene networks that are differentially regulated by CE+BZA treatment compared to Veh treatment. GSEA software was used to identify gene networks with specific functions. Gene set enrichment graphs for networks relevant to NAFLD biology that are (A) downregulated or (B) upregulated by various estrogen treatments are shown. Heatmap of expression of genes that contribute to enrichment score for each GO term are displayed. Fold change relative to Veh treatment of each gene was graphed (mean and range). All data were normally distributed. Statistical significance was established at α = 0.05. One-way Anova with a Dunn’s correction were used to identify treatments that were significantly different from Veh (*P < 0.05, **P < 0.01, ***P <0.001, ****P<0.0001).
Fig 4 Gene ontology (GO) analysis of gene networks that are differentially regulated by CE+BZA treatment compared to Veh treatment. GSEA software was used to identify gene networks with specific functions. Gene set enrichment graphs for networks relevant to NAFLD biology that are (A) downregulated or (B) upregulated by various estrogen treatments are shown. Heatmap of expression of genes that contribute to enrichment score for each GO term are displayed. Fold change relative to Veh treatment of each gene was graphed (mean and range). All data were normally distributed. Statistical significance was established at α = 0.05. One-way Anova with a Dunn’s correction were used to identify treatments that were significantly different from Veh (*P < 0.05, **P < 0.01, ***P <0.001, ****P<0.0001).CC BY · PubMed Central
Fig 5 Whole metabolite analysis of plasma from animals that were treated with different ligands. Blood was harvested from mice six weeks after estrogen treatments. Plasma metabolites were identified by the GC-MS analysis. (A) Metabolomic data was clustered and visualized as a heatmap using Java TreeView. (B) ortho PLSDA analysis of the metabolite data using Metaboanalyst software. (C) Venn diagram analysis to identify distinct and common metabolites regulated by CE+BZA and E2 treatments. (D) Examples of metabolites that are regulated by various estrogen treatments. (E) Examples of metabolites that correlate with liver weight.
Fig 5 Whole metabolite analysis of plasma from animals that were treated with different ligands. Blood was harvested from mice six weeks after estrogen treatments. Plasma metabolites were identified by the GC-MS analysis. (A) Metabolomic data was clustered and visualized as a heatmap using Java TreeView. (B) ortho PLSDA analysis of the metabolite data using Metaboanalyst software. (C) Venn diagram analysis to identify distinct and common metabolites regulated by CE+BZA and E2 treatments. (D) Examples of metabolites that are regulated by various estrogen treatments. (E) Examples of metabolites that correlate with liver weight.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 19

Metadata

Authors
Chen, K. L. A., Zhao, Y. C., Hieronymi, K., Smith, B. P., & Madak-Erdogan, Z.
Affiliations
University of Illinois Urbana-Champaign (US)
Venue
PLOS ONE
Published
2017-12-21
Volume
12
Issue
12
Pages
e0189911
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2779851941
Cited by
19
References
43
Citations by year
2026: 4 · 2025: 1 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 4 · 2019: 1 · 2018: 1
FWCI
1.09
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Pfizer (WI196180)
  • Office of the Vice Chancellor for Research, University of Illinois at Urbana-Champaign (RB15150)
  • National Institute of Food and Agriculture (ILLU-698-909)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
bazedoxifene, conjugated estrogens, estrogen receptor beta agonist, ovariectomy, hepatic steatosis, liver transcriptome, plasma metabolomics, high-fat diet, visceral fat, hepatic lipid accumulation, inflammation, reactive oxygen species, lipid metabolism, estradiol
MeSH terms
Animals, Estrogens, Conjugated (USP), Female, Homeostasis, Indoles, Liver, Mice, Inbred C57BL, Ovariectomy, Mice, Metabolome, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits liver health. https://app.cochat.ai/papers/10.1371/journal.pone.0189911
The paper
Chen, K. L. A., Zhao, Y. C., Hieronymi, K., Smith, B. P., & Madak-Erdogan, Z. (2017). Bazedoxifene and conjugated estrogen combination maintains metabolic homeostasis and benefits liver health. PLOS ONE. https://doi.org/10.1371/journal.pone.0189911

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.